One-year survival and functional outcome after ischaemic stroke according to cancer status: a population-based study (Dijon Stroke Registry)
European Stroke Journal · 02.11.2026 · 11 (11)
DOI: 10.1093/esj/aakag145 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Stroke Journal, online erschienen am 18.11.2026. Verfasst von Sarah Kassir und 3 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Clément-Drevon, Santé Publique France (French Institute for Public Health Surveillance), Institut national de la santé et de la recherche médicale (INSERM) and CHU Dijon Bourg….
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
Cancer is frequent in ischaemic stroke patients. We examined its association with 1-year outcome, and whether it relates to patient characteristics, stroke management or underlying malignancy. Patients and methods Patients were retrieved from the population-based Dijon Stroke Registry, France (2017-2022), and categorised as having no cancer, cancer in remission, active nonmetastatic or metastatic cancer. Primary outcome was 1-year all-cause mortality (Cox regression and day-30 landmark analysis). Secondary outcome was 1-year functional outcome (mRS score, ordinal logistic regression over the full scale and among survivors). Access to acute revascularisation therapy was compared across cancer categories.
Results
Among 1351 patients, 262 (19.4%) had a history of cancer: 10.1% in remission, 5.3% active nonmetastatic and 3.9% active metastatic. One-year mortality rose across groups, from 27.2% without cancer to 29.2%, 41.7% and 64.2%. After adjustment, active nonmetastatic (hazard ratio [HR] 1.58; 95% CI, 1.07–2.32) and metastatic cancer (HR 4.80; 95% CI, 3.30–6.97) were associated with mortality. This strengthened in the landmark analysis. Metastatic cancer was associated with worse functional outcome overall (odds ratio [OR] 9.04; 95% CI, 4.64–17.6). Among the 19 patients with active metastatic cancer who survived to 1 year, no excess disability was detectable (OR 0.71; 95% CI, 0.32–1.60). Revascularisation therapy did not differ significantly by cancer status.
Discussion
The prognostic burden of cancer was graded by disease activity and metastatic extent, and accrued beyond the acute phase, unrelated to acute care. The functional impact of metastatic cancer was largely explained by mortality.
Conclusions
Prognostic assessment stratified by cancer activity and burden is warranted after ischaemic stroke.
Förderung
- Fondation Clément-Drevon
- Santé Publique France (French Institute for Public Health Surveillance), Institut national de la santé et de la recherche médicale (INSERM) and CHU Dijon Bourg…
Zitieren
APA
Kassir, S., Fasolin, C., Duloquin, G., & Béjot, Y. (2026). One-year survival and functional outcome after ischaemic stroke according to cancer status: a population-based study (Dijon Stroke Registry). European Stroke Journal, 11(11). https://doi.org/10.1093/esj/aakag145
Vancouver
Kassir S, Fasolin C, Duloquin G, Béjot Y. One-year survival and functional outcome after ischaemic stroke according to cancer status: a population-based study (Dijon Stroke Registry). European Stroke Journal. 2026;11(11). doi:10.1093/esj/aakag145
BibTeX
@article{Kassir2026,
author = {Kassir, Sarah and Fasolin, Cédric and Duloquin, Gauthier and Béjot, Yannick},
title = {One-year survival and functional outcome after ischaemic stroke according to cancer status: a population-based study (Dijon Stroke Registry)},
journal = {European Stroke Journal},
year = {2026},
volume = {11},
number = {11},
doi = {10.1093/esj/aakag145}
}
EUVIMED